Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of leukocyte biology"
DOI: 10.1093/jleuko/qiac018
Abstract: Our previous phase Ib trial (NCT03222440) showed that radiotherapy plus the anti-PD-1 antibody camrelizumab is a safe and feasible first-line therapy for locally advanced esophageal squamous cell carcinoma. In this study, we divided peripheral CD8… read more here.
Keywords: cell; cell carcinoma; squamous cell; plus camrelizumab ... See more keywords
Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.835889
Abstract: Objective This study was conducted in order to compare the efficacy and safety of transarterial chemoembolization (TACE) plus apatinib plus camrelizumab (TACE+AC) and apatinib plus camrelizumab (AC) in the treatment of unresectable hepatocellular carcinoma (HCC)… read more here.
Keywords: hepatocellular carcinoma; plus camrelizumab; apatinib plus; group ... See more keywords